Profund Advisors LLC Buys 23,440 Shares of Immunome, Inc. $IMNM

Profund Advisors LLC raised its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 121.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,700 shares of the company’s stock after buying an additional 23,440 shares during the period. Profund Advisors LLC’s holdings in Immunome were worth $917,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of Immunome in the fourth quarter valued at about $64,000. Assetmark Inc. acquired a new stake in shares of Immunome in the third quarter valued at about $39,000. BIT Capital GmbH acquired a new stake in shares of Immunome in the third quarter valued at about $69,000. BNP Paribas Financial Markets grew its position in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Immunome in the third quarter valued at about $76,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Up 6.6%

IMNM stock opened at $22.96 on Friday. Immunome, Inc. has a twelve month low of $7.85 and a twelve month high of $27.65. The company has a market cap of $2.60 billion, a PE ratio of -9.65 and a beta of 2.11. The business’s 50-day simple moving average is $21.94 and its 200 day simple moving average is $21.36.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, equities research analysts anticipate that Immunome, Inc. will post -2.26 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IMNM. Craig Hallum raised their price target on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Finally, Truist Financial raised Immunome to a “strong-buy” rating in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome has an average rating of “Moderate Buy” and a consensus price target of $32.82.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.70 per share, with a total value of $103,500.00. Following the completion of the transaction, the director directly owned 43,415 shares in the company, valued at $898,690.50. This represents a 13.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Philip Wagenheim sold 28,200 shares of Immunome stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $20.65, for a total value of $582,330.00. Following the sale, the director directly owned 341,147 shares in the company, valued at $7,044,685.55. The trade was a 7.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 139,438 shares of company stock valued at $2,964,664 in the last ninety days. 7.21% of the stock is owned by corporate insiders.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.